Key figures as of June 30, 2017

 

Cash, cash equivalents and financial assets*

€204.1m

* Including current and non-current financial assets

Financial debt

€4.7m


Staff

171 employees, 3/4 of whom are dedicated to R&D


Portfolio

  • 4 programs in clinical stage including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 1 portfolio of proprietary preclinical programs

See HY 2017 financial results